The effects of resveratrol on lipid profiles and liver enzymes in patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials

• Published in: Lipids in health and disease Vol. 19; no. 1; p. 25
• Main Authors: Akbari, Maryam, Tamtaji, Omid Reza, Lankarani, Kamran B, Tabrizi, Reza, Dadgostar, Ehsan, Haghighat, Neda, Kolahdooz, Fariba, Ghaderi, Amir, Mansournia, Mohammad Ali, Asemi, Zatollah
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 17.02.2020; BioMed Central; BMC
• Subjects: Alanine; Alanine transaminase; Animals; Aspartate; Aspartate aminotransferase; Bias; Blood cholesterol; Blood pressure; Care and treatment; Cholesterol; Cholesterol - blood; Chronic illnesses; Clinical trials; Collaboration; Diabetes; Dietary supplements; Disease; Enzymes; Health aspects; High density lipoprotein; Humans; Hypertension; Insulin resistance; Intervention; Lipid profiles; Lipids; Liver; Liver diseases; Liver enzymes; Low density lipoprotein; Low density lipoproteins; Medical research; Meta-analysis; Metabolic syndrome; Metabolic Syndrome - blood; Metabolic Syndrome - drug therapy; Metabolic Syndrome - metabolism; Metabolic syndrome X; Online data bases; Online databases; Prejudice; Randomized Controlled Trials as Topic; Resveratrol; Resveratrol - therapeutic use; Review; Risk factors; Software; Studies; Supplements; Triglycerides; Triglycerides - blood; Type 2 diabetes; γ-Glutamyltransferase; Iran; Liver enzymes; Metabolic syndrome; Lipid profiles; Resveratrol; Meta-analysis
• ISSN: 1476-511X; 1476-511X
• DOI: 10.1186/s12944-020-1198-x

There are current trials investigating the effect of resveratrol supplementation on lipid profiles and liver enzymes among patients with metabolic syndrome (MetS) and related disorders; however, their findings are controversial. This systematic review and meta-analysis were aimed to determine the effects of resveratrol supplementation on lipid profiles and liver enzymes among patients with MetS and related disorders. We performed a comprehensive search of the following online databases up to November 2018: Cochrane Library, PubMed, Embase, and Web of Science. The relevant articles were assessed for quality of studies using the Cochrane risk of bias tool. Out of 2459 citations, 31 articles were appropriate for including to the current meta-analysis. The pooled results indicated that resveratrol use significantly decreased total cholesterol [weighted mean difference (WMD) = - 7.65 mg/dL; 95% CI, - 12.93, - 2.37; P < 0.01; I : 83.4%] and increased gamma-glutamyl transferase (GGT) concentrations (WMD = 1.76 U/l; 95% CI, 0.58, 2.94; P < 0.01; I : 20.1%). We found no significant effect of resveratrol supplementation on triglycerides (WMD = - 5.84 mg/dL; 95% CI, - 12.68, 1.00; P = 0.09; I : 66.8%), LDL- (WMD = -2.90 mg/dL; 95% CI, - 10.88, 5.09; P = 0.47; I : 96.0%), HDL-cholesterol (WMD = 0.49 mg/dL; 95% CI, - 0.80, 1.78; P = 0.45; I : 74.0%), alanine aminotransferase (ALT) (WMD = -0.14 U/l; 95% CI, - 3.69, 3.41; P = 0.93; I : 79.6%), and aspartate aminotransferase (AST) (WMD = -0.34 U/l; 95% CI, - 2.94, 2.27; P = 0.80; I : 88.0%) concentrations. This meta-analysis demonstrated that resveratrol supplementation among patients with MetS and related disorders significantly reduced total cholesterol and increased GGT concentrations, but did not affect triglycerides, LDL-, HDL-cholesterol, ALT, and AST concentrations. This data suggests that resveratrol may have a potential cardio-protective effect in patients with MetS and related disorders.